• Users Online: 1166
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Contacts Login 
ORIGINAL ARTICLE

Plasma growth arrest-specific protein 6 expression in uremic patients with type 2 diabetes


1 Graduate Institute of Medical Sciences; Division of Endocrinology and Metabolism, Department of Internal Medicine, National Defense Medical Center, Tri-Service General Hospital, Taipei, Taiwan
2 Division of Nephrology, Department of Internal Medicine; Division of Biochemistry, National Defense Medical Center, Tri-Service General Hospital, Taipei, Taiwan
3 Division of Endocrinology and Metabolism, Department of Internal Medicine, National Defense Medical Center, Tri-Service General Hospital, Taipei, Taiwan
4 Division of Endocrinology and Metabolism, Department of Internal Medicine; Division of Biochemistry, National Defense Medical Center, Tri-Service General Hospital, Taipei, Taiwan
5 Department of Orthopedics, National Defense Medical Center, Tri-Service General Hospital, Taipei, Taiwan
6 Graduate Institute of Medical Sciences; Division of Endocrinology and Metabolism, Department of Internal Medicine; Division of Biochemistry, National Defense Medical Center, Tri-Service General Hospital, Taipei, Taiwan

Correspondence Address:
Chien-Hsing Lee,
Division of Endocrinology and Metabolism, Tri-Service General Hospital, No. 325, Sec. 2, Cheng-Gong Road, Neihu District, Taipei 114
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jmedsci.jmedsci_21_19

Background: Diabetic kidney disease is a major cause of uremia worldwide; recently, controversial roles for growth arrest-specific protein 6 (GAS 6) have been revealed in the pathogenesis of diabetic nephropathy. A better understanding of the association between GAS6 and diabetic nephropathy may lead to the development of novel therapeutic approaches for the prevention and treatment of diabetic uremia. Objectives: The aim of this study was to investigate the levels of GAS6 and its role in uremic patients with Type 2 diabetes. Materials and Methods: A total of 109 adults were recruited, of whom 23 had Type 2 diabetes and uremia and 56 had newly diagnosed Type 2 diabetes without remarkable nephropathy; thirty individuals with normal glucose tolerance without significant clinical comorbidities served as controls. Plasma GAS6 concentration and common anthropometric and biochemical variables were analyzed. Results: Plasma GAS6 levels were significantly lower in patients with Type 2 diabetes than in controls regardless of nephropathy (P < 0.001). A trend in declined level of GAS6 among the three groups was also observed. In addition, GAS6 levels were significantly inversely correlated with plasma creatinine, blood urea nitrogen, and uric acid levels in all patients (P < 0.01 for all comparisons). In multivariate logistic regression analysis, higher plasma GAS6 concentration was significantly associated with decreased risk of diabetic uremia, even after adjusting for age, sex, and fasting glucose (C-statistic, 0.72; 95% confidence interval 0.57–0.92;P < 0.01). Conclusions: Our results suggest that plasma GAS6 levels are associated with Type 2 diabetes and may play a role in development of diabetic uremia.


 

  Search Pubmed for
 
    -  Su SC
    -  Hsu YJ
    -  Lu CH
    -  Hsieh CH
    -  Hung YJ
    -  Liu JS
    -  Li PF
    -  Shen PH
    -  Lee CH
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed88    
    PDF Downloaded12    

Recommend this journal